Related Experiment Video

Updated: Aug 20, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

Safety Profile of Mutant EGFR-TK Inhibitors in Advanced Non-Small Cell Lung Cancer: A Meta-analysis

Abubakar Tauseef1, Maryam Zafar2, Peter Silberstein1

  • 1Creighton University, Omaha, Nebraska.

Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS
|November 25, 2022
PubMed
Abstract

Insights

Mutant epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitors show a lower incidence of adverse effects compared to traditional platinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC). These advanced therapies are recommended for patients with EGFR mutations.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Lung cancer remains a leading cause of cancer mortality globally.
  • Platinum-based chemotherapy is a standard treatment but has limitations.
  • Mutant epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitors represent an advanced therapeutic approach.

Purpose of the Study:

  • To evaluate the safety profile of mutant EGFR-TK inhibitors in advanced non-small cell lung cancer (NSCLC).
  • To compare the safety of mutant EGFR-TK inhibitors with platinum-based chemotherapy.

Main Methods:

  • A meta-analysis was conducted.
  • Included 9 phase 3 randomized controlled trials.
  • Focused on patients with advanced NSCLC.

Main Results:

  • Mutant EGFR-TK inhibitors demonstrated a lower incidence of reported adverse effects compared to platinum-based chemotherapy.
  • Adverse effects associated with mutant EGFR-TK inhibitors are generally tolerable.

Conclusions:

  • Mutant EGFR-TK inhibitors are recommended for advanced NSCLC, particularly in patients with EGFR mutations.
  • Manageable adverse effects can be addressed by dose modification or temporary discontinuation.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.1K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K